In the Q&A session facilitated by Dr Cheah Soon Keat, Dr Maximillian Hochmair brought us through the important topics such as determining which patients are suitable for EGFR-TKI sequencing, T790M cut-off value for switching to osimertinib from afatinib and current clinical strategies on patient with L858R mutation.